A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388
Clinical trial NCT07225959 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07225959
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-29
- Primary completion
- 2027-07-01
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.